The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | FRONTIER4: safety & efficacy of Mim8 prophylaxis administered once every two weeks for hemophilia A
In this video, Tadashi Matsushita, MD, Nagoya University Hospital, Nagoya, Japan, briefly introduces the FRONTIER4 trial (NCT05685238), an open-label extension trial assessing the safety and efficacy of Mim8 prophylaxis administered once every two weeks (Q2W) for patients with hemophilia A with or without inhibitors. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
Well, this trial was started a couple of years ago. And all the patients were coming from the Phase I/II trial, which is different from the Phase III trials. So patients frome Phase I or Phase II trials just coming over to this Phase IV trial. And the difference is between the previous trial and the current trial is that we added a new regimen for the Q2W regimen. I mean every two weeks regimen for subcutaneous injection of Mim8 into the patient...
Well, this trial was started a couple of years ago. And all the patients were coming from the Phase I/II trial, which is different from the Phase III trials. So patients frome Phase I or Phase II trials just coming over to this Phase IV trial. And the difference is between the previous trial and the current trial is that we added a new regimen for the Q2W regimen. I mean every two weeks regimen for subcutaneous injection of Mim8 into the patient. So previously the trial was going on either a QW or QM, which is two arms, and we just introduced a new Q2W regimen for patients. And most patients just selected the Q2W regimen, and the result was very successful and without any concern of safety.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Pfizer: Consultancy; Sysmex: Honoraria; CSL: Honoraria; Sanofi: Honoraria; Novo Nordisk: Consultancy, Honoraria, Research Funding; Chugai: Consultancy, Honoraria, Research Funding; Bayer: Consultancy, Honoraria; KM Biologics: Honoraria; JB Pharma: Honoraria; Takeda: Consultancy, Honoraria.
